Skip to main content
Shenzhen Chipscreen Biosciences Co., Ltd. logo

Shenzhen Chipscreen Biosciences Co., Ltd. — Investor Relations & Filings

Ticker · 688321 ISIN · CNE100003LW0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 967 across all filing types
Latest filing 2025-04-25 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688321

About Shenzhen Chipscreen Biosciences Co., Ltd.

https://www.chipscreen.com/en/

Shenzhen Chipscreen Biosciences Co., Ltd. specializes in the discovery and development of original small molecule innovative drugs. The company leverages its proprietary chemical genomics-based drug discovery and early evaluation platform to address unmet medical needs in oncology, metabolic diseases, and autoimmune disorders. Its portfolio includes Chidamide (Epidaza), a selective histone deacetylase (HDAC) inhibitor approved for peripheral T-cell lymphoma and advanced breast cancer, and Chiglitazar (Bilessyl), a novel PPAR pan-agonist for type 2 diabetes. Chipscreen Biosciences maintains an integrated R&D system covering drug discovery, clinical development, and commercialization, focusing on molecular mechanisms and translational medicine to provide novel therapeutic solutions.

Recent filings

Filing Released Lang Actions
第三届董事会第十次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 10th meeting of the 3rd Board of Directors of Shenzhen Microchip Biotechnology Co., Ltd. It includes approvals of various reports such as the 2024 Annual Report, independent director reports, audit committee reports, financial budget reports, ESG report, and other governance and financial matters. The document also mentions that these reports will be submitted to the 2024 Annual General Meeting for approval. The content is focused on board meeting decisions and approvals rather than the reports themselves. The document length is over 11,000 characters, indicating it is not a brief announcement but a comprehensive board meeting resolution notice. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors. It is not the Annual Report itself (10-K), nor a simple announcement of report publication (RPA).
2025-04-25 Chinese
2025年第一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2025 First Quarter Report" of Shenzhen Microchip Biotechnology Co., Ltd. It contains detailed financial statements including balance sheets, profit and loss statements, and cash flow statements for the first quarter of 2025. The report explicitly states it is unaudited and covers the quarterly period from January to March 2025. The content includes comprehensive financial data and analysis typical of an interim or quarterly report. There is no indication that this is merely an announcement or a certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2025
2025-04-25 Chinese
审计委员会对会计师事务所履行监督职责情况的报告
Audit Report / Information Classification · 95% confidence The document is a report from the Audit Committee regarding the supervision of the external audit firm (KPMG Huazhen) for the company's 2024 annual audit. It details the audit firm's qualifications, the committee's evaluation and oversight activities, and the audit process timeline. The document does not contain the actual audited financial statements or the full audit report but rather discusses the audit firm's performance and the committee's supervisory role. The document length is 1822 characters, which is relatively short and more consistent with a supervisory or audit-related report rather than a full Annual Report (10-K) or standalone Audit Report (AR). Given the focus on the audit committee's oversight and the nature of the content, this fits best under Audit Report / Information (AR), which includes standalone audit reports and related supervisory information, excluding full annual reports. FY 2024
2025-04-25 Chinese
关于召开2024年度暨2025年第一季度报告业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling and details of an upcoming earnings explanation meeting (业绩说明会) for the 2024 annual and 2025 first quarter results. It provides the date, time, location, participants, and how investors can attend and ask questions. It does not contain actual financial data or detailed financial statements but rather informs about the event where such information will be discussed. The document length is short (1559 characters) and serves as a notice for the meeting rather than the report itself. Therefore, it fits best into the category of Investor Presentation (IP), as it is a detailed presentation event for investors focusing on financial results and interaction.
2025-04-18 Chinese
关于可转债转股结果暨股份变动的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding convertible bond conversion results and related share capital changes for Shenzhen Microchip Biotechnology Co., Ltd. It details the amount of convertible bonds converted into shares during a specific quarter and cumulatively, as well as the remaining unconverted bonds. It also provides background on the bond issuance and conversion terms. The document is relatively short (1811 characters) and focuses on reporting the conversion results and share capital changes rather than providing a full financial report or detailed analysis. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as convertible bond conversions and share changes. It is not an Annual Report, Interim Report, or Earnings Release, nor is it a regulatory filing or report publication announcement. Therefore, the correct classification is CAP with high confidence.
2025-04-01 Chinese
国投证券股份有限公司关于深圳微芯生物科技股份有限公司2024年度持续督导工作现场检查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "现场检查报告" (on-site inspection report) by the sponsor institution (国投证券股份有限公司) regarding the continuous supervision work for Shenzhen Microcore Biotechnology Co., Ltd. for the year 2024. It details the scope of the inspection, including company governance, internal controls, information disclosure, independence, use of raised funds, related party transactions, guarantees, major investments, and business operations. The document is a formal report of the sponsor's continuous supervision activities as required by regulatory rules for companies issuing convertible bonds and listed on the Shanghai Stock Exchange Sci-Tech Innovation Board. It is not an annual or interim financial report, nor an earnings release or a proxy statement. It is a regulatory compliance and audit-related report by the sponsor institution. This fits the category of an Audit Report / Information (AR), which includes standalone audit or inspection reports and results of regulatory checks excluding full annual reports. The document length is 3226 characters, which is consistent with a detailed report rather than a brief announcement. Therefore, the classification is AR with high confidence. FY 2024
2025-03-04 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.